Document ID: chunk:federal_register_of_legislation:F2025C00036:reg:53
Version: federal_register_of_legislation:F2025C00036
Segment Type: reg
Provision Reference: reg 53
Character Range: 447330–448432

53  Transitional—continuing application of evaluation fees for variations of permissible ingredients determinations
 (1) This regulation applies if, before the commencement of Schedule 5 to the Therapeutic Goods Amendment (2016 Measures No. 1) Act 2017:
 (a) an application had been made under subsection 26BD(1) of the Act (as in force immediately before that commencement) for a variation of a determination under subsection 26BB(1) of the Act; and
 (b) no decision had been made in relation to the application; and
 (c) the evaluation fee prescribed by item 7C or 7D, as the case may be, of the table in clause 3 of Schedule 9 (as in force immediately before that commencement) in relation to the application had not been paid.
 (2) Despite the amendments made by Schedule 3 to the 2017 Amendment Regulations, the evaluation fee prescribed by item 7C or 7D, as the case may be, of the table in clause 3 of Schedule 9 (as in force immediately before the commencement of Schedule 5 to the Therapeutic Goods Amendment (2016 Measures No. 1) Act 2017) continues to apply in relation to the application.